ENहिन्दी soon
Home/India/Answers/GLP 1mg tablet
INIndia Medicines

Is “GLP 1mg” tablet a GLP-1 medicine?

GLP Guidebook teamUpdated 5 Oct 202614 sourcesWritten from published sources
The short answer

No. GLP 1mg is an Indian brand of glimepiride 1 mg, a diabetes tablet from the sulfonylurea group, not a GLP-1 medicine. The US glimepiride label says it works by making the pancreas release insulin, and severe low blood sugar can happen. GLP-1 medicines such as Ozempic (semaglutide) release insulin mainly when blood sugar is high.

Before you go further
  • GLP‑1 medicines are prescription-only in India, not sold over the counter.1
  • A government statement on 1 Apr 2026 said only endocrinologists, internal-medicine specialists and cardiologists can prescribe them.1 CDSCO expert-committee minutes attach a similar condition to some approvals (endocrinologist or internal-medicine specialist), but we found no rule covering every brand.2
  • The risks are in Guide 5: Side effects and risks.
  • Nothing here promises any result.

What is in a GLP 1mg tablet?

Each GLP 1mg tablet contains 1 mg of glimepiride, going by the ingredient line on 3 Indian pharmacy listings we checked on 5 October 2026.3

The listings name Intra Labs India as the company behind it.3 Glimepiride belongs to a group of diabetes tablets called sulfonylureas.4

The US label approves it for adults with type 2 diabetes, alongside diet and exercise. It is not for type 1 diabetes. Your doctor sets the dose; the US label starts at 1 or 2 mg once a day, with breakfast.5

India's National List of Essential Medicines 2022 includes glimepiride 1 mg and 2 mg tablets.6 We found no GLP‑1 medicine on that list.

How is glimepiride different from a GLP-1 medicine?

Glimepiride makes the pancreas release insulin even when blood sugar is normal or low, while GLP‑1 medicines do this mainly when sugar is high.5,7,8

The US glimepiride label says it lowers sugar mainly through insulin release.5 A 2016 review says sulfonylureas do this “even at low plasma glucose levels”.7

The US Ozempic (semaglutide) label calls its insulin effect “glucose-dependent”.8 India's RSSDI-ESI guideline adds that GLP‑1 medicines reduce appetite.9

In a 14-week US label trial, 4% on glimepiride 1 mg had a possible low (hypo), judged by symptoms. It was 16% to 17% on 4 or 8 mg, and 0% on a dummy tablet.5 A 22-week trial with doses up to 8 mg found 20% on glimepiride vs 3% on the dummy.5

People in that 22-week trial gained 1.8 kg on glimepiride; the dummy group lost 0.9 kg.5 In Ozempic's 30-week trial, 2% to 4% on Ozempic alone had a low with symptoms, vs 0% on a dummy.8 The trials counted lows differently, so this is not a head-to-head result.

Among sulfonylureas, India's RSSDI-ESI guideline says glimepiride and gliclazide MR have a lower risk of lows. It prefers them for South Asian patients.9

RisksThe risks, in brief
  • Stomach effects are common on GLP‑1s. Nausea in 16% to 20% on Ozempic vs 6% on a dummy injection (US label).8
  • Pancreatitis (a swollen pancreas) has been seen. The Ozempic label says to stop if it is suspected.8
  • Hypos are more likely when a GLP‑1 is taken with a sulfonylurea such as glimepiride, or with insulin.8
  • Thyroid. Ruled out by the US label for anyone with a personal or family history of medullary thyroid cancer or MEN 2; tell your doctor if this applies.8
Full detail in Guide 5: Side effects and risks →
Not sure what your tablets are?

Build a list of questions for your doctor. Free, no sign-up.

Make my list

How can you tell what a tablet really contains?

Read the generic name on the strip, which Indian rules say must be printed at least two font sizes larger than the brand name.10

On a GLP 1mg strip, that name is glimepiride.3 “GLP” here is only a brand name. GLP‑1 stands for glucagon-like peptide-1 (see the full form and what a GLP‑1 is).9

The GLP‑1 medicine that does come as a tablet in India is oral semaglutide. Novo Nordisk's Rybelsus 3, 7 and 14 mg tablets are approved here for type 2 diabetes.11,12 Torrent launched India's first generic oral semaglutide on 21 March 2026.13

If both kinds are taken together, the Ozempic label warns that the risk of lows goes up. It tells doctors to consider a lower sulfonylurea dose.8 The glimepiride label says lows are likelier if you eat too little, exercise hard or long, or drink alcohol.5

More is in Can GLP‑1 medicines cause low blood sugar? and the type 2 diabetes path.

Get help now: call 112 if someone on glimepiride, insulin or a GLP‑1 becomes confused or faints. Call too for a seizure, or if they are too weak to help themselves. The American Diabetes Association calls a severe low an emergency.14

Read the full picture

Related questions

What is the full form of GLP-1? What is Rybelsus 3 mg used for? Is semaglutide the same as Ozempic? Which symptoms on a GLP-1 need urgent care?
Did this answer your question?

Sources

  1. PIB Research (Government of India). GLP-1 drugs: use, risks, and regulation. 1 Apr 2026. Key takeaways; "Regulation of GLP-1 drugs". static.pib.gov.in
  2. CDSCO. Recommendations of the Subject Expert Committee (Endocrinology & Metabolism): 20–21 Apr 2023, item 1, tirzepatide (cdsco.gov.in · archived copy); 13–14 Feb 2024, items 3–4, semaglutide (cdsco.gov.in · archived copy).
  3. "GLP 1mg Tablet" composition and marketer, as listed by Tata 1mg, PharmEasy and Netmeds (glimepiride 1 mg; Intra Labs India). Pharmacy product listings, checked 5 Oct 2026. Used only for what the brand contains. (Pharmacy pages, not linked.)
  4. Brown & Burk UK. Glimepiride 1 mg tablets, Summary of Product Characteristics (UK), text revised 16 Dec 2020. Section 5.1. medicines.org.uk
  5. Glimepiride tablets, US prescribing information (DailyMed), revised 9/2026. Sections 1, 2.1, 5.1, 6.1 (14- and 22-week trials), 12.1, 14.1. US label, not an Indian one. dailymed.nlm.nih.gov
  6. Ministry of Health and Family Welfare. National List of Essential Medicines 2022. Section 18.3.1, p. 66. cdsco.gov.in · archived copy
  7. Andersen SE, Christensen M. Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis. Br J Clin Pharmacol 2016;82(5):1291-1302. doi:10.1111/bcp.13059 · PMID 27426428. pmc.ncbi.nlm.nih.gov
  8. Novo Nordisk. Ozempic (semaglutide) US prescribing information, revised 05/2026. Sections 4, 5.2, 5.5, 6.1 (Table 2), 7.1, 12.1. US label, not the Indian one: we found no public Indian label. novo-pi.com
  9. RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. Indian J Endocrinol Metab 2020;24(Suppl 1). doi:10.4103/ijem.IJEM_225_20. pmc.ncbi.nlm.nih.gov
  10. CDSCO. The Drugs Rules, 1945, compiled as amended to Jul 2024. Rule 96(1)(i)(A), p. 105. cdsco.gov.in · archived copy
  11. CDSCO. Recommendations of the Subject Expert Committee (Endocrinology & Metabolism), 25 Mar 2025, item 2 (Novo Nordisk, semaglutide tablets): “Semaglutide tablets 3 mg, 7 mg & 14 mg is approved for marketing in India.” cdsco.gov.in · archived copy
  12. Medical Dialogues. Novo Nordisk gets CDSCO panel nod for Rybelsus label update aligned with EMA. 10 Sep 2025. medicaldialogues.in
  13. Torrent Pharmaceuticals. Torrent Pharma launches oral and injectable formulations of Semaglutide (press release). 21 Mar 2026. torrentpharma.com
  14. American Diabetes Association. Severe hypoglycemia (severe low blood glucose). diabetes.org

Last checked 5 Oct 2026 · Next review due 5 Oct 2027 · Report an error

How this answer was made. Written by the GLP Guidebook team from the sources above. It's general information, not medical advice. Talk to a qualified doctor before starting, stopping or changing any medicine. How we write